logo-loader
viewAvacta Group PLC

Avacta's Alastair Smith updates on selection of cancer candidate to take into clinic

Avacta Group PLC's (LON:AVCT) Alastair Smith tells Proactive London's Andrew Scott they've selected the cancer drug candidate they'll be taking into first-in-human clinical trials.

It's an important step for the company as it means they remain on track to submit an investigational new drug/clinical trial application by the end of next year.

Quick facts: Avacta Group PLC

Price: 17.25 GBX

AIM:AVCT
Market: AIM
Market Cap: £20.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19

2 min read